Introduction
The incorporation of the patient perspective in the evaluation of medical products (i.e., drugs, biologicals, 1 devices) is increasingly important and considered essential in many cases. Medical products aimed at 2 relieving patients' symptoms and/or improving levels of self-reported functioning will require measures of 3 patient-reported outcomes (PROs) as endpoints in clinical trials. A PRO instrument systematically collects 4 treatment benefit data directly from patients, without interpretation by clinicians or others (FDA, 2009 ). As 5 stated in the 2009 US Food and Drug Administration (FDA) Guidance for Industry titled Patient-Reported 6
Outcome Measures: Use in Medical Product Development to Support Labeling Claims ("PRO Guidance"), 7 "Use of a PRO instrument is advised when measuring a concept best known by the patient or best 8 measured from the patient perspective" (FDA, 2009) . 9
There is no doubt that the release of the FDA's PRO Guidance has focused increased attention on the 10 development and use of scientifically sound measurement of PRO endpoints in clinical trials. In addition, 11 clinician-reported outcome (ClinRO) measures, observer-reported outcome (ObsRO) measures, and 12 performance outcome (PerfO) measures are receiving increasing attention as well (FDA 2013) . ClinRO 13 measures are completed by clinicians and are often based on clinical interviews (e.g., Hamilton Depression 14
Rating Scale [HAM-D] in depression trials). ObsRO measures are completed by non-clinical informants 15 (e.g., spouse, caregiver, parent, or teacher) and report on observable disease-and/or treatment-related 16 concepts (e.g., activities of daily living inventory completed by caregivers in Alzheimer's disease [AD] trials). 17
PerfO measures are assessments based on a task performed by a patient according to instructions 18 administered by a health care professional. They rely on the cooperation, ability, and motivation of the 19 subject. Examples of PerfO measures include tests of sensory function (e.g., visual acuity), cognitive 20 function (e.g., Digit Symbol Substitution Test in AD trials), and physical performance (e.g., timed 25-foot 21 walk test in multiple sclerosis trials). Although the final PRO Guidance only addressed PRO instruments 22 when it was released in 2009, the FDA held a public workshop in October 2011 where they discussed the 23 need for the same level of evidence: well-defined and reliable measurement for all clinical outcome 24 assessment (COA) tools (i.e., PRO, ClinRO, ObsRO, and PerfO measures) intended to support medical 25 product labeling claims (FDA, 2011; FDA, 2013) . Likewise, this Task Force Report focuses on PRO 26 instruments but the recommendations apply to ClinRO and ObsRO measures as well. 27 In addition to the FDA's increased focus on well-defined and reliable assessment of clinical trial endpoints, 28 one of the most important developments in the field of PRO measurement has been the emergence of 29 technologies that enable the collection of data electronically. Advantages of using electronic data collection 30 include less subject burden, avoidance of secondary data entry errors, easier implementation of skip 2 patterns, date and time stamping, and more accurate and complete data (Hyland et al. 1993; Tourangeau et 32 al. 1996; Taenzer et al. 1997; Bloom 1998; Velikova et al. 1999; Stone et al. 2002; Bushnell et al. 2006; ) . 33
With the increasing availability of multiple modes 1 of PRO data collection, including both paper and various 34 electronic types, the opportunity exists to mix these modes within and across clinical trials in a medical 35 product development program. 36
While mixing of modes within and across clinical trials may meet the needs of global product development 37 programs where the patient population and access to technology vary considerably within and across 38 regions, such mixing may in fact be an avoidable source of measurement error. It is, therefore, the general 39 recommendation of this ISPOR PRO task force report that PRO data collection modes not be varied within 40 a single clinical trial or between trials that seek to pool or compare the data without prior evidence of 41 sufficient measurement equivalence between the modes. 42
This general recommendation is based upon the basic research design tenet that anything with the potential 43 to introduce measurement error into a trial should be avoided (Streiner and Norman, 2008) . Measurement 44 error is, in essence, noise (error variance) that reduces statistical power and attenuates the ability of the trial 45 to detect real change (i.e., treatment effect) in the trial endpoint. In the context of collecting where patients are providing information directlythere are many unavoidable sources of measurement 47 error, including: differences introduced by the need to translate and culturally adapt multiple versions of a 48 PRO instrument; specific cultural biases introduced by differing experiences of the medical condition being 49 studied (Gnanasakthy et al 2013) ; and, the variability in patient's ability to reflect and provide a response. 50
Potential error variance can also be introduced into the trial design by different data collection modes used 51 within the trial that do not provide comparable data (i.e., the modes lack sufficient measurement 52 equivalence.) As the mode of PRO data collection is a part of the research design, it should be possible 53 (even though challenging at times) to decide on and deploy a single consistent mode of PRO data collection 54 in the trial. The recommendation of this task force report is to avoid, where possible, all potential sources of 55 measurement error, including mixed modes of PRO data collection. 56 1 Before proceeding further, a clarification regarding terminology is in order. It should be noted that the term mode of data collection as used in this report differs from the FDA's terminology. The PRO Guidance makes a distinction between PRO instrument administration modes and data collection methods. According to the PRO Guidance, administration mode refers to self-vs. interviewer-administered PRO measurement, while data collection method refers to the tool used for capturing the data such as paper-based questionnaires, web-based data entry, interactive voice response systems (IVRS), or any of the other ePRO devices (FDA, 2009 ). (Note: An interviewer administered PRO measure is not a ClinRO measure because the patient's responses are not interpreted, but simply recorded, by the interviewer.)
We find that the distinction made by the FDA is potentially misleading because the term "mixed methods" in the larger PRO measurement field refers to mixing qualitative and quantitative methods in research. This term is not associated with multiple methods of data collection. On the other hand, the PRO measurement field has a long history of using the term "mixed modes" to refer both to administration, as well as data collection (i.e., ePRO vs. paper). Therefore to simplify the discussion in this report, we use the term mode in the context of both modes of administration per the PRO Guidance and modes of data collection per the PRO measurement field.
3 However, although it may not be optimal, mixing of PRO data collection modes within trials does occur and 57 has to be addressed pragmatically. When modes have been directly compared in cross-sectional studies, 58 there is evidence that PRO data collected electronically can be comparable to that obtained by paper-based 59 data collection, particularly with screen-based devices (Gwaltney et al. 2008 ). However, the literature is not 60 definitive and can be limited by selective reporting; it has been well-documented that studies with positive 61 findings are more likely to be published than those with inconclusive or negative results (Rosenthal 1979; 62 Song et al. 2009 ). In addition, comparability of data collected on different modes is likely dependent on the 63 specific PRO measure being used; hence, a general assumption of measurement equivalence between or 64 among modes may not always hold. While some evidence has shown comparability between paper and 65 visual modes (Gwaltney et al. 2008; Ramachandran et al. 2008) or between paper, Web-based, and/or IVR 66 modes (Bennett et al. 2013a; Bennett et al. 2013b; Lundy and Coons 2011; Lundy et al. 2013 ), more 67 evidence is needed to support mixing modes within a trial setting to ensure it has minimal impact on the trial 68 results. Nevertheless, this task force does not rule out the possibility that, at some point in the future, 69 sufficient evidence will be available to support the assumption of measurement equivalence across modes 70 in most circumstances where an optimal migration has occurred. 71
Further, it is clear that this issue of mixing modes was contemplated by FDA in development of its PRO 72
Guidance. Specifically, the PRO Guidance states that "We intend to review the comparability of data 73 obtained when using multiple data collection methods or administration modes within a single clinical trial to 74 determine whether the treatment effect varies by methods or modes" (FDA, 2009 ). The PRO Guidance 75 does not, however, discuss ways for clinical trial designs to ensure the comparability of the data when 76 mixed modes are used. Although this task force report specifically addresses multiple modes of PRO data 77 collection, it is assumed that many of the same issues are involved when multiple modes of ClinRO and 78
ObsRO data collection are considered. Therefore, this report addresses the key issues in mixing modes, 79 specifically focusing on how to reduce the impact on measurement error when these situations arise. 80
The launching point for this task force report is the prior ISPOR ePRO task force report by Coons et al. 81 (2009) that addressed the evidence needed to support measurement equivalence when migrating from 82 paper to electronic modes of PRO data collection. According to that report, "measurement equivalence is a 83 function of the comparability of the psychometric properties of the data obtained via the original and 84 adapted administration mode. This comparability is driven by the amount of modification to the content and 85 format of the original paper PRO questionnaire required during the migration process. The magnitude of a 86 particular modification is defined with reference to its potential effect on the content, meaning, or 87 interpretation of the measure's items and/or scales." (p 2) Thus, establishing measurement equivalence is 88 essential in demonstrating that the migration from paper to electronic, or for that matter from any data 89 collection mode to another, did not impact the instrument's meaning, interpretation, and resulting 90 responses. In the context of the current task force report, we use the term 'measurement equivalence' to 91 emphasize the need for the instrument to be measuring the same thing regardless of the mode. 92 4 Coons et al. (2009) did not address the issues to take into account when considering mixing two or more 93 modes of PRO data collection in a single trial or across trials intended to be compared or pooled. This 94 current report builds on the recommendations for changing modes of administration in the original ISPOR 95 ePRO task force report by providing additional recommendations regarding good research practices for 96 migration across modes of data collection and an in-depth exploration of the assessment of measurement 97 equivalence between original and migrated versions of PRO instruments, particularly in the context of 98 mixing data collection modes. In addition, we discuss issues that must be considered in order to avoid 99 sources of measurement error that materially impact the meaning and interpretation, and consequently the 100 measurement properties, of the instrument being used to assess PRO endpoints in clinical trials. The report 101 concludes with recommendations for operational and statistical considerations when modes are mixed in a 102 clinical trial setting. The overall objective of the report is to address the use and mixing of data collection 103 modes within and between trials where the PRO endpoints are intended to be used to support medical 104 product labeling. 105
The report is organized as follows: After describing the task force process, we first describe the most 106 common modes of PRO data collection currently available. We then address the factors that should be 107 considered when selecting a mode or modes of PRO data collection in a clinical trial. Next, a summary of 108 how to 'faithfully' migrate instruments is presented, followed by a section on study designs used to evaluate 109 measurement equivalence of the new and original modes of data collection. Finally, we discuss a number 110 of issues that must be taken into account when mixing modes is deemed necessary or unavoidable within 111 or between trials. 112
113

II.
Task Force Process 114 115 <We will describe task force process after the report is finalized.> 116 117 III.
Modes of PRO Data Collection 118
The emergence of new technologies allows trial protocols to be written in which data collection schedules 119 and locations can support more timely and convenient assessment of endpoints. Selecting the appropriate 120 mode of data collection is essential to the success of the trial. Prior to examining the key issues in selecting 121 one or more modes of data collection, we first present those that are most widely available. 122
Paper-and-Pencil 123
While the trend seems to be changing over time, the initial version of most PRO measures has been 124 developed on paper. Hence, self-administration involves a paper questionnaire and a writing implement such as a pencil or pen. Unlike most newer technologies, the data are not captured electronically; the 126 source data remains the completed, hard-copy questionnaire. Written responses on the questionnaire are 127 entered into an electronic database through manual (keyed/typed) data entry or optical scanning. This step 128 has the potential to introduce error associated with secondary data entry. In addition, the lack of real-time 129 electronic notation of the date and time the data are collected is a significant weakness of paper-and-pencil 130 data collection. This is particularly the case with data intended to be collected at relatively frequent intervals 131 in unsupervised settings (e.g., daily symptom diary) as prospective or retrospective (parking lot syndrome) 132 data entry is possible (Stone 2002) . Nevertheless, paper-and-pencil PRO data collection remains 133 prevalent. 134
Digital Pen 135
A hybrid of the paper-and-pencil mode is the digital pen. Like traditional paper-and-pencil data collection, 136 study subjects write their responses on a paper questionnaire but, with digital pen technology, the paper 137 has been specially printed to enable the digital pen to identify where it is on the questionnaire and what 138 response is being written. Hence, other than the need for customized, proprietary printing software, the 139 level of change made to the PRO instrument during migration may be minimal. 140
Digital pens are somewhat thicker than standard pens; they contain a pressure sensor, a camera that 141 captures the written data, a microprocessor, memory, a battery and a ballpoint ink cartridge. Some digital 142 pens also include a Bluetooth transceiver. The responses captured by the pen's camera can be uploaded 143 in real time via a wireless connection or through a pen docking cradle attached (USB) to a computer that 144 uploads the data via the internet to a web-based server. In addition, the completed paper questionnaire is 145 available for verification of any data in question in the case of queries and is often treated as the source 146 data during source data verification processes. 147
Handheld Devices 148
The initial handheld electronic devices, introduced in the late 1980s, were referred to as personal digital 149 assistants (PDAs), and were primarily intended to assist people in managing their calendars, and more 150 broadly, their lives. This platform was adapted to capture diary or field-based data electronically. This was 151 among the first types of electronic PRO data collection -ePRO. Since the 1980s, the small handheld 152 device platform has exploded. These are functionally small platform computers that integrate wireless and 153 telephony capabilities with scaled down user interface (UI) elements. These devices are now mobile 154 computers and telephones, referred to as smart phones. This explosion in platform options, and sizes 155 (while still relatively small to fit in the user's hand), has been leveraged to capture a broad array of PRO 156 data in a broad range of settings. 157 6 Another subset of the handheld device category are purpose built devices such as the Asthma Monitor 3 158 (AM3; manufactured by ERT) and the In2itive eDiary (manufactured by Vitalograph). Both devices are used 159 in respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD) and integrate 160 diary data collection and the ability to capture peak expiratory flow (PEF) readings or forced expiratory 161 volume in 1 second (FEV 1 ) in a single device. These proprietary devices were developed to provide 162 subjects with a single device to collect parallel data streams which can reduce burden in clinical trials. 163
The primary advantage of the small devices is portability. Handheld devices have become the mainstay of 164 electronic PRO data collection, particularly for trials in which frequent field-based data capture is required 165 (e.g., symptom diaries; episodic, event-based diaries). Due to the small size of the screen, usually only a 166 single item/question and its response options are displayed at one time. Responses are typically entered 167 by touching the screen at the appropriate position using a stylus or fingertip; however some older devices 168 require a keypad or keyboard for entry. With wireless and cellular phone technology, data can then be 169 immediately transferred from the handheld device to a central server location. 170
Tablet Computers 171
Tablet computers (aka tablets) are also relatively mobile data collection devices with integrated touch 172 screens that are operated by touching the screen with a stylus or fingertip. The Apple iPad™ is an example 173 of a tablet computer. Tablets are generally smaller than laptop computers but larger than traditional PDAs 174 or mobile phones. This is both an advantage and a disadvantage. The bigger screen size enables larger 175 presentation of items and response options and allows the possibility of multiple items per screen. However, 176 the larger device size decreases its portability/mobility and usability as an off-site data collection mode, 177 particularly for event-based data capture or field-based data collection. 178
Desktop or Laptop Computers 179
The final type of computing platform used to collect PRO data is computers that have larger screens. 180
These generally lack touch screen functionality and utilize UI elements such as a keyboard and/or mouse to 181 enter responses. Within the context of clinical trials, they are not routinely intended to be mobile. Desktop, 182 and more recently, laptop computers, are among the original platforms used for collecting PRO data, prior 183 to the introduction of handheld and tablet devices. Both historically, and today, such platforms are used to 184 capture site-based PRO data. These are typically completed when a subject comes to the investigative 185 site, but such platforms can be used from the subject's home, or anywhere else as well, if the PRO data 186 collection system utilizes Web-based technology. The primary advantage of the desktop or laptop is that 187 the screen size is relatively large, compared to handhelds and tablets, and can accommodate virtually any 188 representation of a PRO instrument. 189
Interactive Voice Response Systems 190
Automated telephone-based data collection is commonly referred to as interactive voice response (IVR). 191 IVR systems interact with callers using a pre-recorded voice question and response option script. Contrary 192 to IVR's name, a touch-tone response entry using the phone's keypad, not voice, is the primary response 193 mechanism currently used. An assumption may be that future voice recognition technology will allow for 194 true interactive voice capability for this data collection mode. IVR systems can be implemented to allow 195 incoming or outgoing calls. Hence, trials can be designed such that the study subject is called at data 196 collection time points, the subject places the call at data collection time points, or both. Some of the 197 advantages of IVR systems are that no additional hardware is required for the subject other than a landline 198 or cellular/mobile telephone, little if any, subject training is necessary, and data are stored directly to the 199 central database. 200
Stand-Alone vs. Web-based Systems 201
The previous descriptions of PRO data collection options have focused on the form factor, either the size of 202 the computer, or whether the system uses auditory or visual representation of the PRO instrument. Another 203 dimension of PRO data collection systems worthy of consideration is whether the system is stand-alone or 204
Web-based. In this context, a stand-alone system is self-contained with all of the software and functionality 205 located in the device (although often with a link to web-based database and management systems) vs. a 206 Web-based system where the device is simply a vehicle to access the system through a Web browser. 207
This distinction is important and worth mentioning here because there is a substantial difference in the 208 control of the presentation of the PRO instrument between these systems. With a stand-alone system, the 209 subject will only have access to the PRO instrument from the specific device on which it is deployed for that 210 trial, whether a handheld, tablet, desktop, or laptop. There will be consistency of the presentation and 211 interface with the PRO instrument. In contrast, with a Web-based system, there are a number of variations 212 that warrant consideration. One typical implementation is the use of a browser (e.g., Internet Explorer) to 213 access a central system that then displays the PRO instrument on a Web-enabled device screen. 214
The subject can potentially utilize multiple device types (though this may be restricted to selected 215 browsers/technologies), and therefore, the presentation and interface with the PRO instrument can vary 216 within the trial. Such Web-based systems can, depending on the variability of devices allowed to access 217 the PRO instrument, functionally be different modes of PRO data collection. Thus, the Web-based system, 218
while potentially offering considerable flexibility for completion of the PRO instrument, can also, in some 219 circumstances, be considered a mixed mode of PRO data collection. The amount of error variance caused 220 by this issue is unknown and worthy of further research if we are to move to this more flexible system. It 221 8 should also be noted that many Web-based systems cannot be utilized where there is no internet access 222 and require a constant internet connection in contrast to stand-alone systems that can be used offline. 223
Mobile Applications ("apps") 224 225
Another, more recent, option is the downloading of a software application, also known as an "app," to a 226 smartphone device (e.g., Apple iPhone™ or Android phone). The user runs the app locally on the device 227 and completes the PRO instrument. The data are then transmitted via the internet or cellular signal. When 228 the app is downloaded onto the smartphone, the questionnaire resides on the device and the device 229 becomes, in essence, a stand-alone system. There is increasing interest in developing such instrument 230 apps for PRO data collection, which would allow subjects to use their own technology with which they are 231 comfortable and familiar, rather than having to carry around yet another device. This approach is gaining 232 momentum in what are called "bring your own device" (BYOD) trial contexts (Taylor 2013) . The use of such 233 apps in BYOD trial settings has not yet been fully evaluated by the scientific community nor the FDA, but it 234 has significant potential. 235
IV. Process for Selecting the Appropriate Mode of Data Collection 236
The selection of a PRO-based clinical trial endpoint measure and the mode of PRO data collection should 237 not be an afterthought in a drug development program. All too often, the PRO data collection mode 238 appears to be given insufficient attention with providers of ePRO technologies and services asked to 239 accomplish the near impossible prior to the launch of a trial. Hence, as early as possible, a substantial 240 amount of thought and deliberation should be invested in the selection and evaluation of the mode of PRO 241 data collection for a clinical trial. A lead time of 6 months is ideal as ePRO development activities are front-242 loaded and must occur prior to the launch of the trial. There are a number of factors that must be 243 considered, including patient population, location of data collection, characteristics of the instrument (e.g., 244
length, format of responses/answers), data collection schedule (which is driven by the type of outcome 245 being assessed), feasibility, and cost. 246
Patient Population 247
The primary consideration for selection of a PRO data collection mode is the patient population that will be 248 asked to provide the self-reported data. The characteristics of clinical trial subjects, particularly sensory and 249 physical abilities, will be important drivers of the choice of modes. It should be noted that this is not a new 250 consideration. Historically, when data collection mode options were limited to paper and pencil, or an 251 interviewer reading to the patient, we had a limited ability to respond to the variability in patients' 252 capabilities. Given the diversity of options now available, we can (and should) be more responsive to the 253 patient population's needs. For example, subjects that have non-correctable visual or hearing impairments 254 will require an auditory or visual based data collection system, respectively. Furthermore, in conditions 9 where there are decrements in physical function (e.g., joint stiffness, tremors) or patients' physical abilities 256 are compromised, such as rheumatoid arthritis or Parkinson's disease, both the selection and the specifics 257 of the data collection mode will be important. Auditory systems may be good for such patients, or visual 258 systems that have larger font sizes for reading or larger stylus sizes for arthritis sufferers would be helpful. 259
Location of Data Collection 260
In a clinical trial, PRO data may be collected from subjects at the investigative site (e.g., clinic), in the field 261 or away from the study site (e.g., subject's home or workplace), or both. At the study site, the portability of 262 the data collection mode is not as critical; hence, all modes are potentially viable. However, if the data 263 collection takes place in the field, then subject convenience and portability are important considerations. 264
The Characteristics of the PRO Instrument 265
The characteristics of the PRO questionnaire can be a critical driver in selecting the mode of data collection. 266
With regard to the length of the PRO instrument, both the number of items and the amount of time 267
necessary to complete the items should be considered. It should be noted that subject burden is an issue 268 to bear in mind, regardless of the data collection mode. Raymond (2010) makes the distinction between 269 "questionnaires" and "diary-type reports," with the latter comprising fewer concepts with questions that are 270 completed at least daily. Handheld devices have become the mainstay of field-based data collection 271 (eDiaries) in clinical trials, but they are less than optimal for longer PRO instruments. Long and time-272 consuming questionnaires can be physically and/or cognitively fatiguing and should be avoided. Likewise, 273
there may be aspects of the data collection mode to consider that may mitigate or aggravate the fatigue 274
factor. 275
Depending on the length or complexity of the response options, screen size can be a limitation. If 276 information on a screen is needed to inform or interpret the task or content on a subsequent screen, the 277 implementation of the PRO instrument is far from optimal (Tiplady 2010). Hence, the response options 278 should appear on the same screen as the question. Scrolling to access response options should not be 279 required. In the context of IVR systems, memory may be required to enable the subject to select among 280 response options; numerous or lengthy response options complicate task completion. In addition, there are 281 some types of response formats that are not easily operationalized on all data collection platforms. For 282 instance, a traditional visual analog scale (VAS), which is a line with descriptive anchors at each end (e.g., 283
"No pain" to "Pain as bad as it could be") with no intermediate positions along the continuum, does not lend 284 itself to administration on an auditory system (e.g., IVR).. Open-ended or free-text responses tend to be 285 more burdensome on tablets and handheld devices because an on-screen keyboard is required for text 286 entry. 287
Data Collection Schedule 288
The frequency of protocol-driven data collection points in a clinical trial should also be considered. 289
Technology has enabled greater flexibility and functionality for designing trials with more frequent data 290 capture. Trial protocols may require that PRO data is collected monthly, weekly, daily, or multiple times per 291 day. Within a day, data capture can be scheduled for specific times (e.g., 7 AM and 7 PM) or based on an 292 event (e.g., bowel movement) or symptom (e.g., pain). The choice of mode must consider the multiple 293 places where the subject may be when the data collection is to occur. Hence, for multiple data collection 294 points during the day, the portability of the device is a major consideration assuming the patient is mobile. 295
Feasibility of Implementation 296
Another consideration for mode selection is the infrastructure available in the selected locale of an 297 investigative site or in the trial more broadly. Some regions within a country and some countries more 298 broadly may not be able to support certain technologies. For example, if high-speed internet access or a 299 cellular phone network is critical for a data collection technology, this will be a criterion for selecting this 300 mode in trial or at a specific site. Variability in feasibility of implementation across investigative sites within 301 a trial can potentially lead to mixing of modes. 302
Cost 303
The reality of conducting clinical trials is that cost will be a factor in determining the mode of data collection. 304
While this is less than ideal with regard to choosing the optimal mode to collect high quality data, cost is, 305 nonetheless, a significant driver for selecting a mode. The team making the mode of data collection 306 decision will need to balance the above selection criteria against available funds to make the best decision 307 for a specific circumstance. 308
It should be noted that if a less expensive option is chosen early in a medical product's development, the 309 team will need to consider using a different mode (i.e., mixing modes) later in the program. It is likely that 310 choosing one mode of data collection will be more cost effective than multiple modes in the same trial. 311
Furthermore, it cannot be assumed that paper mode of data collection will always be less expensive than an 312 electronic mode; there are hidden costs with paper including the time required for secondary data entry into 313 the system and time spent on "data cleaning" and queries prior to database lock. Therefore, when cost 314 comparisons are made, the full cost of a data collection mode(s) accrued across the lifetime of the study --315 not just the upfront costs associated with ePRO implementations --should be taken into consideration. 316
Finally, it should be noted that the costs associated with electronic modes of data collection change as 317 technology evolves. 318
After the appropriate mode of data collection has been selected, the next step in the process is to migrate 319 the PRO instrument to the newly selected mode before implementing PRO measurement in the planned 320 clinical trial program, assuming the chosen mode is a new one for the PRO instrument. In some instances, 321 multiple modes may be selected for data collection and migration may occur concurrently. Following 322 migration, it is important to assess if the new mode has measurement equivalence with the original mode, 323 that is, subjects interpret and respond to the instrument the same way regardless of the mode.
V. Migration 325
The discussion of the optimal migration process is relevant to the discussion of potentially using mixed 326 modes because it is necessary to migrate and evaluate measurement equivalence before mixing so that the 327 desired modes are available and appropriate for use. Since there is little, if any literature, available on the 328 migration process, these recommended good practices are based on previous successful migrations 329 conducted by members of the task force that led to demonstrations of measurement equivalence. 330
The goal of any migration is to have minimal or no impact on the measurement characteristics of the 331 instrument. A "faithful migration" refers to the development of alternative modes of data collection that do 332 not introduce response bias that results from changes in the way the instrument is presented/formatted or 333 how the subject interacts with it. The most common path is migrating from paper to electronic modes, but 334 migration from one electronic mode to another or from electronic to paper will occur. The primary goal of 335 the migration process is to ensure that subjects interpret and respond to the questions/items on the PRO 336 instrument the same way regardless of data collection mode. It is possible to evaluate this by conducting 337 cognitive interviews with subjects from the target population and/or assessing response equivalence 338 between modes. 339 Furthermore, it is possible to achieve measurement equivalence even if the instructions or item presentation 340 may not be the same as the original mode. In fact, there may be an opportunity to present items or 341 instructions within the instrument more clearly in a specific data collection mode. For example, if the 342 instrument has a skip pattern, the electronic version could show only the items that subjects need to 343 complete; that is, if there are any skips or jumps over items based upon a previous answer, the subject will 344 never see the item. This can avoid completion of a non-relevant item and resulting data entry queries due 345 to conflicting responses. Such enhancements may bring clarity to instrument completion, but leaves the 346 instrument 'faithful' to its original intent and meaning. 347
This section on migration issues builds on the recommendations of the previous ISPOR ePRO Task Force 348
Report (Coons et al., 2009) to provide more detailed guidelines for the "faithful migration" process and to 349 discuss the mixing of data collection modes, particularly the special considerations when mixing paper and 350 electronic modes. 351
Perform a "Faithful Migration" 352
Most migrations involve making changes to the PRO instrument that are required due to characteristics of 353 the new mode. A "faithful migration" is conducted carefully to ensure that only necessary changes to the 354 format and instructions are made--item and response content has not changed. A "faithful migration" of an 355 instrument does not need to look exactly like it did originally, but it does need to collect the same data.
12
The degree of modification is a key consideration in determining the level of evidence needed to evaluate 357 equivalence as presented by Coons et al. (2009) , and is a direct result of the migration process. For 358 example, migrating from paper to an IVR presentation has been categorized as a moderate modification 359 (Coons et al, 2009 ) because the necessary changes are more extensive than with most other data 360 collection modes. Modification includes revisions to the instructions and may include non-substantive 361 changes to wording of questions and responses for effective implementation on the IVR system. These 362 changes, along with the change from visual to auditory cognitive processing, may result in systematic 363 differences in responses between the modes (Coons et al, 2009 ). However, it should be noted that 364 traditional telephone-based data collection using a live interviewer rather than the recorded scripts of an IVR 365 system would require the same type of changes. 366
The following are recommended steps to conduct a "faithful migration": 367 1. Contact the instrument's developer/copyright holder to obtain licensing and/or permission to conduct 368 the migration and to determine if there are requirements for the migration process. 369 370 Some instrument developers are now restricting which modes are suitable for migration, and in 371 some cases, which vendors are permitted to conduct such migrations. It is essential to obtain all 372 information related to conducting a migration well before beginning the process to ensure the 373 appropriate procedures are followed. In cases where an instrument is in the public domain or has 374 no identifiable copyright holder or licensor, the sponsor and ePRO vendor must proceed using their 375 best judgment to conduct a "faithful" migration without instrument developer involvement or 376 approval. 377 378 2. Review the original version of the instrument to identify necessary changes that need to be made to 379 suit the new mode. 380
The most common changes are to revise the instructions to be suitable to the new mode and to 381 present one item at a time on a handheld device rather than multiple items per page or in a grid 382 format as is often done on paper. For example, paper questionnaires often instruct the subject to 383 circle a response or to check/tick a box to choose his or her response. Either type of wording will be 384 confusing on an electronic device, so the instructions are reworded to read "select a response", 385 which can be understood across most modes of data collection. Moving from a grid format on paper 386 to a single item per screen presentation may require rewording of items if a format is used in which 387 the item stem begins at the top of the page and the remainder of each item continues as a fragment 388 in the grid below. In such cases, a complete question will need to be formed from each part of the 389 grid, and the responses are typically presented in a vertical scale rather than horizontally as on the 390 grid. 391 13 3. Contact instrument developer/copyright holder for approval of wording and formatting changes 392 needed to migrate the instrument to the chosen platform. 393
The copyright holder's approval is necessary to ensure that the proposed changes are considered 394 appropriate and do not threaten the validity of the instrument. The copyright holder may have 395 preferred solutions to the changes proposed so that consistency can be maintained across 396 migrations conducted by separate ePRO vendors. 397 4. Conduct the migration process and generate draft screens or script. 398
Once approval for wording changes is obtained, draft screens or a draft script for IVR should be 399 generated to show how the migrated instrument will look or sound in the new mode. The following 400 recommendations help to ensure a "faithful migration" takes place: At this stage, collaboration between the instrument developer/copyright holder and the ePRO vendor 419 is critical to ensure that the migration has been done faithfully and that the new format of the 420 instrument appears to retain the same intent and meaning of the original. There may be several 421 iterations of draft screens/scripts and rounds of review to meet the needs of the instrument 422 developer for the migrated format. 423 6. Finalize electronic version on electronic mode. 425
The final stages of ePRO implementation include developing the requirements documentation, 426 programming in the mode of data capture and conducting user acceptance testing in the final 427 platform prior to implementation in usability studies or in the eventual clinical trial. User acceptance 428 testing ensures that the system is operating according to the specifications. However, further 429 testing, either usability testing or feasibility testing (see below) will still need to be conducted to 430 ensure that the specific intended target population can use the system to complete the migrated 431
instrument. 432
See Appendix A for a checklist of steps in the migration process. 433
Further cognitive interviewing, usability testing, and/or equivalence testing, may be required to confirm that 434 the migration has been faithful and the new implementation is capturing the same kind of data as the 435 original. These are addressed in later sections of this report. 436
Mode Specific Considerations for Migration 437
In addition to the process outlined above, each mode has specific considerations that must be addressed 438 during the migration process. The four most common modes will be addressed here. 439
Migration to a Smartphone/Handheld Device 440
The main factor for consideration in migrating to a smartphone/handheld device is the space constraints of 441 the smaller screen. Regardless of how the instrument was originally formatted on paper, the default on a 442 handheld device is one item per screen with all responses visible on the same screen. In some cases, a 443 long item with long response options will pose a great challenge as it is not possible to fit all of the text of 444 the question and responses on the screen at the same time. Some solutions are to display the item on the 445 first screen and responses on the second screen with a reminder of what the question was asking, or to 446 present partial responses on a line with a popup that displays the entire response for clarification. 447
Another possibility is to allow scrolling on the screen to accommodate longer questions or to view response 448 options that do not fit on the small screen. Scrolling is not ideal as it greatly increases the risk that subjects 449
will not be aware that it is necessary to scroll to view the missing text or response options. It also increases 450 the risk of subjects interpreting the question differently or answering differently. 451
As previously mentioned, migration from some paper-based questionnaires will require the rejoining of split 452 item stems, as illustrated in Figure 1 . In addition, due to space constraints of the screen, response options 453 must be displayed vertically instead of horizontally as in the original presentation. Nevertheless, the 454 possibility of utilizing a landscape format in order to take advantage of wider screen real estate should not 455 be ruled out. Figure 2 also illustrates a case where the recall period "past 4 weeks" is not bolded on the handheld device format although it was bolded on paper, as some platforms are not able to render this type 457 of formatting in the electronic version. 458 Due to the larger screen area available, a decision needs to be made in consultation with the instrument 472 developer regarding whether to present one item per screen or to present multiple items per screen on the 473 tablet. With larger size tablets it may be possible to display the entire page as it appeared on the paper 474 version, with radio buttons or checkboxes for responding. A grid format can be retained on the tablet, 475 although it may not be possible to retain all items on the screen as on paper. 476
It is important to remember that a "faithful migration" does not necessarily mean that the electronic version 477 must look the exact same as the paper version. It means that all of the language from the paper version 478 has been retained, and the migration does not impact the way in which the subject enters the data. 479
Presenting multiple items per screen may save time with a very long questionnaire, but it also runs the risk 480 of missing data or confusion. It may not be clear to the subject that multiple responses need to be selected 481 on the same screen. Moreover, if functionality is not programmed to prevent skipping questions or 482
advancing to the next screen without completing all questions, the risk of missing data is increased. 483
On the other hand, a tablet presentation allows for larger fonts and more space to display text, so there are 484 fewer concerns over fitting the instructions, question and responses on the same screen. However, it 485 should be noted that although space may be available for multiple items per screen on a tablet, a single 486 item per screen can provide consistency across multiple screen-based migrations of the instrument. 487
Consistent presentation, i.e., less variation in the presentation of an instrument's items across different size 488 screen-based devices, is optimal and a recommendation of this task force, especially if more than one data 489 collection mode is being used in a clinical trial. 490
Migration to a Web-based Format 491
While Web-based instruments appear to be device independent, there are still constraints contingent on the 492 type of device used to access the Web interface. Due to the wide range of browsers, devices, and screen 493 sizes, a decision needs to be made whether to allow certain types of browsers, such as those for mobile 494 devices, to access the instrument. The screen design for a Web-based instrument intended to be viewed on 495 a desktop or laptop computer would be more similar to a tablet design due to the assumption of more 496 screen space available. However, the screen design for a mobile device like an iPhone would be closer to a 497 smartphone implementation and would require one item per screen formatting. 498
Due to the wide range of screen sizes and formats with Web-based instruments, there may be greater risks 499 of differences in interpretation of scales. For example, the VAS is scored by measuring the point selected 500 on a line. Line length will vary greatly by screen size and browser. This could lead to different responses in 501 relation to the overall length of the line. As stated previously, it is best to use the single item per screen 502
format because it provides the potential for less variation in presentation across different screen sizes. 503
Migration to an IVR System 504
For IVR systems, subjects respond to recorded scripts by using, primarily, zero through nine on the 505 telephone keypad. For the most part, migration considerations for IVR have to do with the manner in which 506 the item text (stem) or response options are formatted. For example, if the item is in the form of a 507 statement, it may make more sense to rephrase it in the form of a question: "I feel tired" becomes "Did you 508 feel tired?" 509
With regard to the response options, if a verbal rating scale is used, the responses must be associated with 510 numeric entries and these must be incorporated into the IVR script for the instrument. In the case of a 511 numeric rating scale that has each end of the scale anchored by a descriptor (e.g., 0= "None" and 10= 512 "Worst imaginable"), but no descriptors in between, the script needs to describe that response context 513 clearly. For example, such items are often worded as follows: Use a scale from zero to ten where zero 514 means none and ten means worst imaginable. 515
In addition, a traditional visual analog scale, with verbal anchors on each end and no demarcations or 516 descriptors at interim points, cannot be effectively operationalized on an IVR system without changing it to a 517 numerical rating scale. On a technical level, if responses require pressing two or more numbers on the 518 keypad (e.g., 10), the script should confirm with the subject the intended response since one of the numbers may not have been recorded by the system (e.g., only "1" was recorded rather than the intended "10" due to 520 insufficient pressure on the keypad). 521
Usability vs. Feasibility 522
When performing a migration from one data collection mode to another, establishing the subject's ability to 523 use the new mode, or usability testing, is an important component of the migration. Coons et al. (2009, p 524 423) stated: "Usability testing examines whether respondents from the target population are able to use the 525 software and the device appropriately. This process includes formal documentation of respondents' ability to 526 navigate the electronic platform, follow instructions, and answer questions. The overall goal is to 527 demonstrate that respondents can complete the computerized assessment as intended." Usability testing is 528 an indication of the subject's ability to navigate or use a particular data collection system. Since it is 529 focused on the respondent's ability to use the system, it may be conducted at an investigative site, in a 530 controlled environment with observation of the subject. 531
While usability testing is always recommended to establish subjects' (or end users') ability to use the 532 system, feasibility testing, or the evaluation of the system within a specific study design, may only be 533 necessary in certain circumstances. The distinction between these two types of testing is best 534 characterized as follows: usability testing assesses whether the data collection mode can work under 535 general conditions, whereas feasibility testing assesses whether it will work in the context of a specific study 536 design or a specific instrument. 537
The need for feasibility testing will be driven by the novelty of the study design in which the PRO data 538 collection system is to be implemented. For example, if the system is to be implemented for site-based 539 PRO data collection in a standard study design that has been previously implemented in numerous trials, 540 there may be no need for additional feasibility testing. As a counter example, if the system is to be 541 implemented in a novel study design, where field-based data is being collected in a unique way (e.g., 542 multiple times per day) for a given patient population, then feasibility testing will ensure that that PRO data 543 collection system actually works with the patients in the study design and using the new instrument. Thus, 544 the evaluation of whether or not to conduct feasibility testing, in addition to usability testing, will be case-by-545 case and driven by the novelty of the study design and the instrument. 546
If feasibility testing is deemed as necessary, the testing plan should include: recruiting subjects similar to 547 those who will participate in the clinical trials; subjects following the study procedures as required by the 548 study design for a reasonable period of time (e.g., using the diary for 7 days); and then performing 549 debriefing interviews with the subjects to assess their compliance with the study procedures (e.g., if they 550 completed the diary every day, as requested) as well as to assess usability. The debriefing of the subjects 551 is best facilitated by review of actual compliance data captured during the study and likely reported on a 552 portal of some kind. 553
It is important to note that neither usability testing nor feasibility testing as described above is the same as 554 another process called user acceptance testing (UAT) 2 . According to Coons et al. (2009, p. 424) , "the 555 purpose of UAT is to determine whether the software complies with the written system specification or user 556 requirements document." It is not intended to determine if respondents like or can use the system. UAT 557 does not include clinical study subjects. We recommend that usability testing and, if necessary, feasibility 558 testing, occur in addition to user acceptance testing, following a migration to a data collection mode. 559
VI.
Equivalence 560
Any migration process involves some type of modification(s) to implement the instrument in the new mode. 561
The goal of the "faithful migration" is that subjects interpret and respond to the questions/items on the PRO 562 instrument the same way regardless of data collection mode. Once a migration has occurred, it is 563 necessary to determine if this goal was achieved through an evaluation of the measurement equivalence 564 between the original and migrated modes. The previous ISPOR Task Force Report focused on the degree 565 of modification as the key factor in determining the level of evidence needed to establish equivalence. In 566 this section, we build upon the work of that previous task force and recommend additional considerations for 567 determining the level of evidence needed to establish equivalence. We also delineate the types of 568 equivalence testing and the typical procedures to execute such work. 569
Need to Establish Equivalence 570
One consideration is whether measurement equivalence needs to be established between the original and 571 new data collection mode. In the context of instruments that will be used in registration trials for submission 572 to the FDA, measurement equivalence must be established and documented by the study sponsor if the 573 data are to be used to support labeling for a medical product. If there are sufficiently rigorous published 574 data to support that equivalence, then further equivalence studies are not needed. A decision tree is shown 575 below in Figure 3 . It is worth noting that from a scientific perspective, we believe that it is always necessary 576 to have confidence, through evidence, that measurement equivalence exists because this has a direct 577 impact on interpreting any results from a migrated instrument (represented by always following the right 578 hand side of Figure 3) . 579 
Levels of Equivalence Evaluation
582
Following the "faithful migration" and the determination that equivalence needs to be established, the 583 appropriate level of equivalence evidence needs to be identified. The level of equivalence evidence is 584 dependent on the extent that the changes or modifications are likely to have had an effect on the subjects' 585 interpretation and responses to the items in the instrument. 586 Table 1 below summarizes the levels of modification that might occur during "faithful migration," and is an 587 adapted version of the one presented by Coons et al. (2009) . In the course of performing the migration, 588 two types of changes may occur and need to be considered when equivalence is evaluated: format and 589 procedural. Format changes refer to differences between the modes in terms of format, including how the 590 items and responses are presented to the subject. For example, formatting modifications include adapting 591 instructions from a paper to an electronic mode, such as changing 'circle' to 'select.' Procedural changes 592 refer to the different ways modes are actually implemented in studies and include aspects such as edit or 593 validation checks, introducing a jump or skip sequence so subjects do not see questions that are not 594 relevant to them, completion windows, and compliance with protocol requirements such as when to 595 complete data collection. In general, the procedural changes between modes may have a greater impact on 596 how the subject responds to questions because the electronic modes can limit possible responses to those 597 20 that are within an appropriate range, prevent unintentionally skipped questions, and enforce completion 598 windows; none of these are/were possible with paper. 599
The breadth and extent of the modifications made during the migration process, some of which are 600 necessary and others that facilitate easier administration of the instrument, will vary in terms of their impact 601 on influencing the subject's interpretation and responses. Table 1 incorporates examples of minor and 602 moderate levels of procedural as well as format modifications to illustrate how both types of changes can be 603 evaluated in terms of levels of equivalence. Minor modifications have a low likelihood of affecting 604 interpretation and response, and therefore cognitive interviews and usability testing are sufficient to confirm 605 the equivalence between the modes. Moderate modifications introduce the possibility of affecting 606 interpretation and response, and therefore it is recommended that a quantitative equivalence study along 607 with usability testing be conducted to evaluate equivalence between the modes. 608
It is critical to determine the level of equivalence needed as part of the equivalence study planning process. 609
The table below is based upon Coons et al. (2009) , and additional detail has been added to illustrate what 610 constitutes minor and moderate modifications. In cases where modifications fall into more than one level, 611 the recommendations associated with the higher level of modification and, therefore, evidence should be 612 followed. It must be noted that if substantial changes to the item content and/or response options are 613 needed to enable migration of the instrument to a new mode of data collection, the instrument is considered 614 a new instrument and full psychometric evaluation would be necessary. 615 
Types of Measurement Equivalence Studies 617
Two major types of studies may be conducted to evaluate measurement equivalence between modes: 618 1) Qualitative studies involve cognitive interviews that provide qualitative data to evaluate equivalence 619 between modes. These studies have previously been associated with minor degree of modification 620 between modes. 621
2) Quantitative studies are intended to evaluate statistical equivalence of responses, and involve much 622 larger sample sizes and focus only on statistical comparison of responses to both modes of the PRO 623 measure. 624
Equivalence Study Descriptions 625
Common Qualitative Study Designs 626
Qualitative studies involve small samples of 10 to 15 participants who are from the target population of the 627 confirmatory clinical trial, usually Phase 3. Qualitative study designs are used to evaluate the impact of 628 format changes between the original mode and the migrated mode to ensure that the subject's 629 interpretation of the items on the migrated mode is comparable to the original. 630
Cognitive Interviews during the Instrument Migration Process 631
It bears pointing out that cognitive interviews conducted during the instrument migration process serve a 632 different purpose than cognitive interviews conducted during the instrument development process. In 633 general, cognitive interviewing techniques are used to study the way in which subjects "understand, 634 mentally process, and respond" to materials presented to them (Willis 2005, p 3) . Of interest here are the 635 cognitive interviews conducted subsequent to instrument migration, which are aimed at determining if 636 subjects are interpreting and responding to the items the same way on the new mode as they would on the 637 mode from which the instrument was migrated. See below for different cognitive interviewing approaches. 638
In contrast, cognitive interviewing during instrument development is primarily aimed at supporting the 639 instrument's content validity by determining if subjects are interpreting items and using response scales as intended. In the current context, cognitive interviews are not intended to revisit the content validity of the 641 original instrument. 642
One approach to conducting cognitive interviews involves having subjects complete the instrument on the 643 original mode and new mode of data collection and determining if there are items for which the responses 644 differ between the two modes. A distraction task can be included between completion of the modes to 645 reduce potential memory/carryover effects yet allow a short interval between administrations to reduce 646 subject burden. The interview then focuses on those items individually to determine if the different 647 responses were random (i.e., "I could go either way") or systematic due to a difference in the meaning or 648 interpretation of the item by the subject on the alternative modes. 649
If the latter is the case with a substantial number of subjects in the cognitive interview sample, the changes 650 made in migrating those items to the new mode need to be re-visited to determine if a successful migration 651 of those items is possible. It should be noted that, other than using the responses on the two modes to 652 identify where differences exist, this approach is not quantitative; the responses are not used for any 653 descriptive or inferential statistical analyses. Further, if such discrepancies between modes occur and 654 changes are made, the cognitive interviewing must be replicated. It there are still discrepancies in subject 655 qualitative reporting due to format differences, a quantitative equivalence study should be considered (see 656 below). 657
A second approach involves having subjects complete the instrument on the new mode and asking them 658
how they interpret what each item is asking them. This can be accomplished by asking the subject to 659 repeat the question being asked in their own words (i.e., paraphrasing) or through a think-aloud task which 660 involves the subject talking through how he or she arrives at the response (Willis 2005) . The subject's 661 interpretation of the item is then compared to the item definition or concept elaboration document prepared 662 by the instrument developer to determine if there is concordance. This approach more closely parallels 663 cognitive interviewing during the instrument development process. It assumes that documentation of the 664 intended meaning/interpretation of the items is available. If the instrument had been translated for use in 665 other languages/cultures, such documentation should exist since it is essential for linguistic validation. If it 666
does not exist, it should be able to be constructed in conjunction with the instrument's developer. 667
A third approach is to ask subjects only about instructions and/or items that were modified during the 668 migration process to reduce subject burden and interview length. This enables a more focused 669 investigation of the potential impact of those changes and a potentially shorter interview. Subjects are 670 asked to read both versions of the instructions or items on the two modes and identify any perceived 671 differences in the self-report task or in the interpretation/meaning of modified items. However, if most or all 672 of an instrument's items required modification during the migration process, then this approach does not 673 necessarily decrease the amount of time required to conduct the cognitive interview because all such items 674 would still require debriefing. 675
At the present time there is no consensus regarding the optimal approach to cognitive interviewing during 676 the migration process. A combination or hybrid of two or more of the above is a viable option if it makes 677 sense for a particular study. 678
Common Quantitative Study Designs 679
Quantitative equivalence studies are recommended for moderate modifications between the modes (see 680 Table 1 ) when migrating and for mixing modes that involve visual vs. auditory use (IVR), use of Web at 681 subjects' homes, and for paper vs. electronic diary studies. All of these scenarios present greater risks for 682 differences in response between modes and therefore a greater need to demonstrate that they provide 683 sufficiently equivalent results. 684
Within quantitative equivalence study types, Coons et al. (2009) mentions randomized cross-over and 685 randomized parallel groups as the typical options for evaluating equivalence. Randomized cross-over 686 designs have become the preferred study design for migration equivalence studies because subjects serve 687 as their own controls and therefore the sample size is significantly reduced. Within the randomized cross-688 over approach, study designs may be either single visit when evaluating if the migration changed 689 interpretation or multi-visit when evaluating if migration changed interpretation and how items were 690 completed in the context of implementation. The multi-visit study design is most useful for evaluating field-691 based assessments which are intended to be completed on a daily basis over a period of time and scores 692 are typically averaged. 693 Figure 4 depicts the most common study designs for quantitative equivalence studies. The single visit study 694 design is appropriate for a site-based or field-based assessments and involves a randomized cross-over in 695 which each study subject completes both modes of data capture but is randomized to the order of 696 completion (i.e., randomized to which mode is completed first to control for order effects). 697
The multi-visit study field evaluation design is appropriate for diary or field based instruments, if there is a 698 need to establish that the two modes of data collection are equivalent in the context of a simulated study 699 design. The multi-visit study involves a randomized cross-over in which each subject is randomized to 700 order and completes the first mode for one to two weeks and then crosses over to complete the second 701 mode for the same length of time. This approach is recommended in cases where the two modes are 702 intended to be mixed in future studies. 703
Due to the longer study duration, it is important to also assess whether the subject's condition has changed 704 to ensure that the comparisons made are within those subjects who have not changed during the course of 705 the study. This approach allows for procedural differences between the modes to be tested in setting similar 706 to what the subject would experience in the clinical trial. However it has an increased risk of demonstrating 707 a lack of equivalence because of the potential for larger response differences between the two modes due 708 to the manner in which the subjects are completing data entry.
For example, if a protocol has subjects entering data within a specific time window per day, data entry with 710 an electronic data collection device may be confined to that time window whereas with a paper-based data 711 collection, data may be entered by the patients at any time. (This study design functionally includes the 712 concept of feasibility, examining performance of the system in the context of a specific study design, as 713 discussed above. Therefore, the situations in which a multi-visit equivalence study design is incorporated 714 should be carefully considered.) 715
Single visit studies answer a different question from multi-visit study designs. Single visit studies focus on 716 equivalence in interpretation at a point in time, which is sufficient when moving away from the paper-based 717 data collection, whether at the site or in the field. Multi-visit studies are needed to address equivalence 718 between modes in a field-based context of a specific study design, and are needed if intending to mix 719 modes in the future. More specifically, if one intends on mixing paper and electronic diaries in a trial, the 720 multi-visit feasibility study is needed to establish equivalence of these two modes of PRO data collection in 721 a real-life setting, given the procedural differences between the two modes. (Again, this will also 722 functionally accomplish the goal of feasibility testing of the electronic data collection mode.) 723
In either case, similar statistical methods such as those proposed in Coons et al. (2009) and McEntegart 724 (2010) , are used to evaluate the equivalence between responses. 725 it may be helpful to conduct a "double cross" study in which each subject crosses between modes and then 731 back to the original mode so that test-retest reliability can be obtained and compared for both within and 732 between modes. See Appendix B for details on the "double cross" study design. 733
When planning subject recruitment for qualitative and/or quantitative equivalence studies, it is important to 734 consider potential overlap with recruitment for clinical trials with the same patient population, especially in 735 rare disease where the population for trials is limited. It is acceptable to recruit subjects for equivalence 736 studies who may then go on to participate in a clinical trial in which the modes tested in the equivalence 737 studies are to be used, in order not to reduce the pool of potential clinical trial participants. Unless it is 738 absolutely necessary, it is not recommended to recruit participants for equivalence studies who have 739 already participated in a clinical trial or validation study using one of the modes in question because they 740 have already experienced the mode and PRO instrument being studied and may have a biased response 741 during the equivalence study. 742
Qualitative study designs are acceptable for demonstrating measurement equivalence for minor 743 modifications and for migrations in which the original and alternative data collection mode are not intended to be combined in clinical trials. These studies do not statistically test measurement equivalence for mixed 745 modes and are insufficient for mixed paper and electronic field-based assessment (e.g., daily diary) to be 746 used within the same trial. Within quantitative study designs, if a field-based assessment is tested in a 747 clinic-based single visit design, it does not reflect the actual trial setting and is unlikely to assess the true 748 performance of the instrument. 749
It is also critical for field-based assessment studies that the subject population is stable and unchanging to 750 limit true change in response in equivalence studies, but clinical trial use assumes that subjects will change 751 over time due to the treatment. Therefore it may be impossible to distinguish what is driving change in 752 scores when mixed paper and electronic field-based assessments are used in a treatment setting. The 753
result of the equivalence studies may be to conclude that the potential differences between paper and 754 electronic field-based assessments are too great to allow mixing modes within a clinical trial, and in these 755 cases the default should be the electronic data collection mode only. 756
As the term migration in and of itself merely refers to the transfer of an instrument from one mode or format 757 to another, it carries no implication of what will be done with either mode in the future. In many cases, the 758 migration results in a new mode that will replace the original mode in future studies, while mixing involves 759 using both old and new modes within or between studies and then pooling the data from different modes for 760 analysis. Therefore, when migrating permanently it is only necessary to demonstrate equivalence for 761 prospective use, while when migration results in mixing modes, it is necessary to demonstrate equivalence 762 for concurrent use. In the former case, a qualitative study may suffice, while in the latter case it is necessary 763
to conduct a quantitative equivalence study. Therefore, it is strongly recommended that the potential for 764 mixed modes be considered at the start of the equivalence study planning process so that the appropriate 765 approach to evaluating equivalence, qualitative or quantitative, will be used in the most timely and efficient 766 way. 767
VII.
Mixing 768 While mixed modes can and do occur in all research settings, the primary focus of this paper is on clinical 769 trials in which the PRO endpoints are intended to support labeling claims. The discussion thus far regarding 770 mixing modes has focused on mixing within a given trial. The general recommendation is to avoid, where 771 possible, such mixing due to the increase in measurement error associated with introducing any variable 772 into a study. 773
We note that mixing, as used in this report, refers to the administration of the same instrument via different 774 data collection modes in a single clinical trial; it does not refer to the administration of different instruments 775 via different data collection modes in a single clinical trial. The latter does not pose a threat to 776 measurement error as discussed in this report.
Our recommendations thus far for mixing have focused on determining the need to establish measurement 778 equivalence when mixing occurs. It could be argued that randomization of subjects into groups is sufficient 779 to account for mixing. As long as the pattern of mixing modes is the same in the treatment and control 780 groups, any potential measurement error introduced by the mixed modes will be comparable across the two 781 groups. However, even the balanced introduction of measurement error across treatment arms has the 782 potential to put the trial at risk of not showing a treatment effect if the signal to noise ratio is decreased. Any 783 change during the trial (after randomization) that leads to different data capture mode patterns across the 784 treatment and control patients (or within treatment or control patients) has the potential to differentially 785 introduce measurement error. 786
There are a number of ways in which mixing of modes can occur in development of medical products, 787
including mixing: e) timepoints within a trial (e.g., start with one mode and change to another mode). 796
We now turn to a discussion of the various ways in which modes might be mixed. 797
Mixed modes occurring between medical product development programs or clinical trials within a program 798 are often the result of evolving technology. New and better methods of PRO data collection emerge or 799 regulatory requirements change and modes may change during the product development program. The 800 implementation of mixed modes in these situations can be carefully planned and executed with supporting 801 studies to demonstrate the equivalence of modes. 802
In this manner, if the old or original mode is abandoned, a demonstration of measurement equivalence 803 supports consistency of interpretation of the data between trials, and no additional activities are needed in 804 new trials because only a single mode of PRO data collection is being incorporated. In some development 805 programs, there may not be a need to compare current trials to previous ones with respect to the PRO data. 806
If that is the case, then there is no need to establish measurement equivalence between the new mode, and the one used in previous trials. The need for measurement equivalence will be driven by the need to 808 compare data across trials within the program. 809
The remaining types of mixing are within a given clinical trial. The first that we will consider is mixing modes 810 across countries within a trial. When conducting multi-country studies, not all countries may have access to 811 the technology being implemented for PRO data collection (e.g. Internet access for Web-based version). In 812 such cases, specific countries within multi-country studies may need to collect PRO data using one mode 813 while the remaining countries use another. Measurement equivalence should be demonstrated across 814 mode. Historically, researchers considered mixing technology-based solutions with paper-based solutions if 815 a specific country is not able to support the selected technology. 816 However, with careful planning, the modes that are mixed may have only minor differences (e.g., both are 817 screen-based systems), and thus, a lower likelihood of introducing measurement error resulting from 818 measurement inequivalence. For example, if a Web-based PRO data collection system is the default for 819 the trial, perhaps a handheld or tablet can be used for countries that do not have internet access that can 820 support the Web-based system. 821
Within a country, modes can also be mixed between participating clinical sites within a trial, again, because 822 of access to the specific technology, or possibly the site's ability. If the issue is site ability, then the potential 823 mixing of electronic solutions becomes more challenging. The likely case is that the investigative site does 824 not believe they can implement the technology-based solution. It may be possible to have more similar 825 technology solutions that a site can implement, which, again, will minimize the potential for introducing 826 measurement error. 827
Alternatively, the sponsor may choose to mix paper and electronic solutions. If the PRO data will be field-828 based assessment, our general recommendation still prevails; it is unlikely that equivalence can be 829 established. In such cases, it may be prudent for the sponsor to consider other options such as not 830 including the specific site or region in question. (This also applies to the country case described above.) In 831 contexts where the subject sample is extremely difficult to recruit, such as for rare diseases, the sponsor 832 may be faced with a significant dilemma between mixing modes and increasing measurement error, versus 833 obtaining the subjects for the trials. In such cases, the sponsor will need to make this decision based upon 834 the specific issues facing them. 835
Subjects within a given investigative site may have the need for various modes of PRO data collection 836 because of subject ability, preference, state of health, or site preference for a given subject. Such 837 decisions to mix subjects within a given site should have been anticipated and planned for in a similar 838 manner to the above cases of mixing across countries or sites. If mixing of modes within a site is 839 anticipated, then appropriate upfront equivalence should be established.
The additional challenge, however, is deciding that a subject needs one mode or another. We can 841 anticipate that in these cases, the request will be for a familiar mode of PRO data collection, likely paper. If 842 a potential subject has never previously used an electronic method of data collection, then his or her initial 843 preference may be to select paper, if that is the other option presented in the trial. Such subject preference 844 would not be based upon actual ability to utilize the electronic solution, but a subject's impression or belief. 845
We recommend that rather than letting the subjects decide, a more objective method of evaluating 846 individual subject's ability be used if a sponsor wants to provide options to subjects. Such an evaluation 847 can take the form of having the subject attempt to use the electronic method at the investigative site. 848
If this evaluation demonstrates that the subject cannot use the primary electronic solution, possibly because 849 of subject ability or state of health, then the investigative site should establish that the subject can use the 850 alternative mode. It should be emphasized to the investigative site that this evaluation is mandatory so that 851 the site does not attempt to use its own, idiosyncratic evaluation of subject ability/competence to make this 852 decision. We recommend that mixing modes of PRO data collection within an investigative site be used 853 rarely and approached cautiously. 854
In the final situation for consideration, subjects may begin a study using one PRO data collection and finish 855 with another. Some trials have built in a paper back-up solution for situations where the technology fails, 856
given that one potential issue for any electronic PRO data collection system is failure of the technology. 857
Thus, some subjects may begin in one mode but switch to another as a backup in cases of device loss or 858 failure, or inability to access the electronic version. In such situations, it will be important to note where such 859 a switch took place within the duration of the trial. 860
Further, more recent advances in both technology, as well as delivery of technology, may facilitate a more 861 reliable technology back-up (e.g., a Web-based system as a temporary replacement for a stand-alone 862 system), or quick recovery back to the same technology. The primary issue is one of the potential for 863 missing data versus the introduction of measurement error through mixed modes of data collection. The 864 sponsor will need to consider a back-up solution, and what solution most appropriately balances those two 865 considerations. The sponsor may decide that a backup solution that minimizes missing data takes priority 866 regardless of the nature of the backup. In addition, a low level of mixing of modes (e.g., <10%) may not 867 have an impact on the overall result, but sensitivity analyses are recommended to verify whether it did or 868 not, especially if equivalence has not been shown a priori. 869
Any one of these types of mixing can yield differences in the data and introduce measurement error into the 870 trial or clinical program results. We therefore recommend that the need for data comparability and the 871 impact of introducing measurement error be assessed for each situation. Our recommendation is that if 872 data are to be compared or pooled at any level, quantitative evidence of equivalence is necessary. Table 3  873 provides a presentation of the risk of not having equivalence at each level at which mixing may occur. 876 Table 3 above suggests situations that vary in risk when using mixed modes for measurement of PRO 877 endpoint(s) between and within a clinical trial. This could be the difference between success and failure for 878 the trial if it is the primary endpoint. As mentioned in the introduction, not having measurement equivalence 879 between the modes could increase measurement error, in turn attenuating the ability to identify a treatment 880 effect within a given trial. Such measurement error could then result in a non-significant difference in the 881 primary efficacy PRO endpoint for a new medical product. 882
Types of Modes Being Mixed 883
Once it is determined that mixing will be done either between or within a trial, there are considerations for 884 which types of modes to mix. We now turn to issues to consider with mixing various types of modes of PRO 885 data collection across the situations just described. This includes mixing paper and electronic modes and 886 different electronic modes of data collection.
Mixing Paper and Electronic 888
Mixing paper and electronic modes is the most risky combination because of the differences in how a 889 subject interacts with paper, having little to no restriction on how he or she responds to questions, in 890 comparison with electronic modes, which verify responses via edit checks and restrict the subject in how 891 they may respond to questions. Our general recommendation is to avoid mixing paper and electronic 892 modes of data collection to the extent possible. There is less risk in mixing site-based instruments because 893 they are completed under supervision and corrections to invalid responses can be made, and if equivalence 894 between these modes has been previously demonstrated. 895
Empirical evidence is emerging to demonstrate moderate to good correlations between paper and Web-896 based data collection for site-based instruments (Bennett 2013a; Bennett 2013b) . We strongly discourage 897 the mixing of paper and electronic field-based assessments because of the significant potential equivalence 898 issues, the significant procedural change between these two modes, and the likelihood they will not 899 generate equivalent responses. 900
The FDA clearly discourages field-based PRO data collection using paper because of the inability to know 901 when the data are entered. Specifically, the PRO Guidance (2009, p 14) states "If a patient diary or some 902 other form of unsupervised data entry is used, we plan to review the clinical trial protocol to determine what 903 steps are taken to ensure that patients make entries according to the clinical trial design and not, for 904 example, just before a clinic visit when their reports will be collected." This quote specifically addresses the 905 ill-advised use of paper as the single data collection mode, but it also underscores the impracticality of 906 mixing paper and electronic diaries in a clinical trial setting. 907
Mixing Electronic Modes 908
Mixing visual modes, such as tablet with the Web or a smartphone device, is less risky because it is 909 potentially easier to demonstrate equivalence between these modes and implement them in a similar 910 fashion so that differences in format are minimized. However, the use of the Web without restrictions on 911 screen size and resolution is potentially risky because it is not possible to control all elements of the visual 912 presentation to ensure that all subjects see the questions and responses the same way. 913
We recommend caution when using Web-based data collection for this reason and consider it a mixed 914 modes situation because of the degree of differences. Mixing visual and auditory modes, such as Web and 915 IVR, requires that quantitative equivalence be demonstrated to ensure that the moderate difference 916 between modes does not impact interpretation and response. Some studies have demonstrated 917 equivalence between Web and IVR modes (Bennett et al 2013a; Bennett et al 2013b) . There may also be 918
implementation challenges with such disparate modes that need to be considered. 919
If proceeding with mixing modes, it is important to implement data collection carefully in the trial itself in a 989 planned manner at the country level or higher and minimize ad hoc mixing by sites or individual subjects. 990
Finally, when mixing occurs it must be addressed in the statistical analysis plan for the trial and the ability to 991 pool the data must be evaluated in order to then evaluate treatment effects with mixed modes data. A 992 successful mixed modes trial requires a "faithful migration," measurement equivalence established between 993 modes, and carefully planned implementation to minimize the risk of increased measurement error. 994 APPENDIX A.
Checklist of Recommended Steps to Conduct a "Faithful Migration" "Faithful Migration"
Step Considerations 1.□ Contact the instrument's developer/copyright holder to obtain licensing and/or permission to conduct the migration and to determine if there are requirements for the migration process.
Some instrument developers are now restricting which modes are suitable for migration, and in some cases, which vendors are permitted to conduct such migrations. It is essential to obtain all information related to conducting a migration well before beginning the process to ensure the appropriate procedures are followed.
2.□
Review the original version of the instrument to identify necessary changes that need to be made to suit the new mode. The copyright holder's approval is necessary to ensure that the proposed changes are considered appropriate and do not threaten the validity of the instrument. The copyright holder may have preferred solutions to the changes proposed so that consistency can be maintained across migrations conducted by separate ePRO vendors.
4.□
Conduct the migration process and generate draft screens or script.
□ Retain exact wording of item (questions/stem and responses) where possible □ Retain the order of response options □ Keep question and response options together on the same screen □ Evaluate need for instructions on the same or different screens due to space constraints □ Consider aesthetic elements such as spacing between question and responses, space between response options, and equal spacing of response options to reduce bias □ Ensure font size and screen resolution are legible □ Keep text length in mind for future translations □ Use navigation buttons that are easily understood 5.□ Send draft screens or IVR script to instrument developer/copyright holder for review and approval.
There may be several iterations of draft screens/scripts and rounds of review to meet the needs of the instrument developer for the migrated format. This should be taken in to consideration when developing the timeline.
6.□
Finalize electronic version on electronic mode. □ Develop the requirements documentation □ Program in the mode of data capture □ Conduct user acceptance testing
